Charles River to acquire Frontage's bioanalysis and DMPK operations for $470 million
The deal, announced November 9, 2026, adds Exton, Pennsylvania testing sites and could carry up to $75 million more in performance-based payments.
Charles River Laboratories International said on November 9, 2026 that it had signed definitive agreements to buy the bioanalysis and DMPK business of Frontage Holdings Corporation, located in Exton, Pennsylvania, for about $470 million in cash, subject to customary closing adjustments.1 The deal also includes additional payments of up to $75 million tied to how the acquired business performs in the future.1 Charles River expects the transaction to close in the first half of 2027, pending shareholder and regulatory approvals and other customary conditions.1
The assets being acquired include a CLIA-certified central laboratory and two sites in Exton, Pennsylvania spanning roughly 150,000 square feet with about 340 employees.1 The businesses being purchased made up approximately 40% of Frontage's total 2025 revenue of $256.7 million.1
On structure, Frontage is a publicly traded company listed on The Stock Exchange of Hong Kong.1 Charles River is working alongside Hongkong Tigermed Co., Limited, described as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd., and Dr. Song Li in a consortium arrangement to take Frontage private first1, with Charles River later ending up owning the Exton bioanalysis and DMPK assets after restructuring. The companies plan to carry this out through a court-sanctioned scheme of arrangement that would take Frontage private and withdraw its Hong Kong Stock Exchange listing.1 After privatization closes, the parties intend to split Frontage's businesses into separate subsidiaries, with Charles River retaining the bioanalysis and DMPK units while Tigermed and Dr. Song Li take the remaining operations.1
Financially, Charles River said the deal is expected to be neutral to non-GAAP earnings per share in 2027 and accretive after that1, and plans to fund the purchase and related fees through its credit facility and available cash.1 The acquired business is expected to be folded into Charles River's DSA segment.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.